Patents Assigned to Eisai R&D Management Co., Ltd.
  • PYRIMIDINE FGFR4 INHIBITORS
    Publication number: 20200206222
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Application
    Filed: December 17, 2019
    Publication date: July 2, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dominic REYNOLDS, Ming-Hong HAO, John WANG, Sudeep PRAJAPATI, Takashi SATOH, Anand SELVARAJ
  • Method for Predicting Effectiveness of Angiogenesis Inhibitor
    Publication number: 20200199689
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • FORMULATION COMPRISING LIPOSOMES
    Publication number: 20200188300
    Abstract: A formulation comprising liposomes, wherein the liposomes comprise, based on the liposome, 0.7 to 3.0 mol % of eritoran or a pharmaceutically acceptable salt thereof and 0.5 to 3.0 mol % of a PEGylated phospholipid.
    Type: Application
    Filed: December 13, 2019
    Publication date: June 18, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Hiroshi Ishihara, Katsura Hata, Hiroki Muto, Geoff Hird
  • Intermediates in the synthesis of eribulin and related methods of synthesis
    Patent number: 10676481
    Abstract: The invention relates to methods and intermediates useful in the synthesis of eribulin.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 9, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Phil S. Baran, Charles E. Chase, Francis G. Fang
  • LEWY BODY DISEASE THERAPEUTIC AGENT CONTAINING PYRAZOLOQUINOLINE DERIVATIVE
    Publication number: 20200155541
    Abstract: Provided is a therapeutic agent for Lewy body disease comprising (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: May 21, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Yukio Ishikawa
  • MACROCYCLIC COMPOUND AND USES THEREOF
    Publication number: 20200148698
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
    Type: Application
    Filed: April 3, 2018
    Publication date: May 14, 2020
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Salts of indazole derivative and crystals thereof
    Patent number: 10640483
    Abstract: The present invention provides salts of (E)-N,N-dimethyl-4-((2-((5-((Z)-4,4,4-trifluoro-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)pyridin-2-yl)oxy)ethyl)amino)but-2-enamide represented by the formula I and acids, and crystals thereof, possessing a potential to be used as drug substance in pharmaceuticals.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: May 5, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventor: Keiko Onuma
  • Tetrahydropyrazolopyrimidine compounds
    Patent number: 10640500
    Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 5, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Roch Boivin, Eric Carlson, Atsushi Endo, Hans Hansen, Lynn D. Hawkins, Sally Ishizaka, Matthew Mackey, Sridhar Narayan, Takashi Satoh, Shawn Schiller
  • DEMENTIA THERAPEUTIC AGENT COMBINING PYRAZOLOQUINOLINE DERIVATIVE AND DONEPEZIL
    Publication number: 20200129501
    Abstract: There is provided a therapeutic agent for Alzheimer's disease and Lewy body dementia for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (1): or a pharmaceutically acceptable salt thereof, and donepezil represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 30, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • DEMENTIA THERAPEUTIC AGENT COMBINING PYRAZOLOQUINOLINE DERIVATIVE AND MEMANTINE
    Publication number: 20200129488
    Abstract: There is provided a therapeutic agent for Alzheimer's disease for combined use of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinoline-4(5H)-one represented by formula (I): or a pharmaceutically acceptable salt thereof, and memantine represented by formula (II): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 30, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mai Miyamoto, Sadaharu Kotani
  • CHIRAL REAGENTS FOR PREPARATION OF SUBSTITUTED PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS
    Publication number: 20200115405
    Abstract: A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi ENDO, Robert T. YU, Francis FANG, Hyeong Wook CHOI, Mingde SHAN
  • Compounds for the treatment of cancer
    Patent number: 10618930
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 14, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B
    Patent number: 10611773
    Abstract: The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves subjecting a non-macrocyclic intermediate to a carbon-carbon bond-forming reaction (e.g., an olefination reaction (e.g., Horner-Wadsworth-Emmons olefination), Dieckmann reaction, catalytic Ring-Closing Olefin Metathesis, or Nozaki-Hiyama-Kishi reaction) to afford a macrocyclic intermediate. The invention also provides compounds useful as intermediates in the synthesis of eribulin or a pharmaceutically acceptable salt thereof and methods for preparing the same.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: April 7, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Francis G. Fang, Dae-Shik Kim, Hyeong-Wook Choi, Charles E. Chase, Jaemoon Lee
  • Lyophilized formulation of HGF
    Patent number: 10610569
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: April 7, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Revascularization graft material
    Patent number: 10610618
    Abstract: Provided is a graft material capable of securing a sufficient space for regenerated tissue in the implantation site, and thereby promoting the regeneration of a blood vessel. Specifically, the present invention provides a revascularization graft material including an outer tube and an inner tube each being formed by knitting twisted yarns of biodegradable single yarns into a hollow tubular structure, wherein there is provided, in the lumen of the outer tube, at least one inner tube having an outer diameter smaller than the lumen diameter of the outer tube. The inner tube functions as a core material for the outer tube, and accordingly the revascularization graft material is excellent in kinking resistance, and the occlusion of the lumen hardly occurs.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: April 7, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Hiroshi Onodera, Eri Nishioka
  • PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITOR
    Publication number: 20200078306
    Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 30, 2018
    Publication date: March 12, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Edgar Schuck, Robert Lai, Ishani Savant Landry, Bhaskar Rege, Mai Miyamoto, Sadaharu Kotani, Kanta Horie
  • CONTAINER
    Publication number: 20200062442
    Abstract: Provided is a container including a main body, a lid body, and a fixing mechanism that fixes the lid body to prevent the lid body from opening from the main body when the lid body is closed, the fixing being released when the lid body moves to a front side with respect to the main body. Cutouts are formed in side plates of the main body. The container is configured such that, by a rear plate tilting forward toward the cutouts of the side plates, the lid body moves to the front side with respect to the main body and the fixing of the lid body is released, and as the rear plate and a top plate of the lid body form a single plane, the top plate rises and the lid body opens.
    Type: Application
    Filed: January 5, 2018
    Publication date: February 27, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Takahisa Sakaguchi
  • CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER
    Publication number: 20200055883
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 16, 2018
    Publication date: February 20, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • STEREOCHEMICALLY DEFINED POLYPROPIONATES AND METHODS FOR MAKING AND USING THE SAME
    Publication number: 20200055866
    Abstract: The present invention relates to stereochemically defined polypropionates and methods for preparing and using the same. The stereochemically defined polypropionates may be useful in the synthesis of natural products and/or natural product-like libraries.
    Type: Application
    Filed: July 25, 2019
    Publication date: February 20, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Francis G. FANG, Hyeong-wook CHOI, Silvio CAMPAGNA, Steven MATHIEU
  • Crystalline FGFR4 inhibitor compound and uses thereof
    Patent number: 10562888
    Abstract: A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-yl)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: February 18, 2020
    Assignee: Eisai R&D Management Co., LTD.
    Inventors: George Moniz, Kristen Sanders, Arani Chanda, Kenshi Yoshida